Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of HA115 in Healthy Volunteers
NCT03567694Phase 1Withdrawn
- Sponsor
- Conjupro Biotherapeutics, Inc.
- Start
- Oct 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HA115 in asthma (2 arms), sponsored by Conjupro Biotherapeutics, Inc. Primary endpoint: Adverse event (AE) at 36 days. Planned start Oct 2021; status: withdrawn.
02
Drugs
HA115
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03567694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567694.